U.S. markets closed
  • S&P 500

    +6.29 (+0.13%)
  • Dow 30

    +48.44 (+0.13%)
  • Nasdaq

    -49.91 (-0.32%)
  • Russell 2000

    -9.40 (-0.47%)
  • Crude Oil

    +0.98 (+1.27%)
  • Gold

    -3.30 (-0.16%)
  • Silver

    -0.23 (-0.98%)

    +0.0008 (+0.08%)
  • 10-Yr Bond

    +0.0500 (+1.17%)

    +0.0010 (+0.08%)

    +0.3690 (+0.25%)
  • Bitcoin USD

    -749.88 (-1.44%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    -56.70 (-0.73%)
  • Nikkei 225

    -101.45 (-0.26%)

HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023

  • Revenue for Q3 2023 increased to $6.9 million, up from $2.2 million in Q3 2022.

  • Research and Development expenses rose to $24.6 million, reflecting a $6.3 million increase year-over-year.

  • Cash, cash equivalents, and restricted cash stood at $108.1 million as of September 30, 2023.

  • Net loss widened slightly to $19.1 million in Q3 2023 from $18.3 million in the same period last year.

On November 9, 2023, HOOKIPA Pharma Inc (NASDAQ:HOOK) released its financial results for the third quarter of 2023, showcasing both progress and challenges in its operations. The company, which specializes in developing a new class of immunotherapeutics, reported an increase in revenue and higher research and development expenses, alongside a modest increase in net loss compared to the same quarter in the previous year.

Financial Summary

HOOKIPA Pharma Inc (NASDAQ:HOOK) reported a notable increase in revenue for the third quarter of 2023, with figures reaching $6.9 million, up from $2.2 million in the third quarter of 2022. This growth was primarily attributed to the partial recognition of upfront and milestone payments from collaborations with Gilead and Roche, as well as cost reimbursements for activities related to the preparation of a first human trial under the Roche collaboration.

However, the company's research and development expenses also saw a significant rise, totaling $24.6 million for the quarter, which is $6.3 million higher than the previous year's figure. This increase was driven by higher clinical study expenses for HOOKIPA's HB-200 program and increased spending for Roche partnered programs. Despite these higher expenses, general and administrative costs remained stable at $4.9 million.

The net loss for the quarter was $19.1 million, a slight increase from the net loss of $18.3 million reported in Q3 2022. The increase in net loss is primarily due to the rise in research and development expenses.

Operational Highlights

Joern Aldag, Chief Executive Officer at HOOKIPA Pharma, expressed satisfaction with the company's HB-200 program, citing "consistent and strong data" and promising response rates in cancer patients. He also highlighted the company's upcoming milestones and the potential of its arenaviral platform technology to address unmet needs in cancer and infectious diseases.

Liquidity and Capital Resources

The company's cash position as of September 30, 2023, was reported at $108.1 million, a decrease from $113.4 million at the end of 2022. The reduction in cash reserves was primarily due to cash used in operating activities, partially offset by funds from a follow-on financing in June 2023.

Looking Ahead

While HOOKIPA Pharma Inc (NASDAQ:HOOK) is preparing for a randomized trial expected to begin next year, the company is also focused on achieving significant milestones across its portfolio. The financial results and business developments reported in this quarter reflect the company's ongoing commitment to advancing its pipeline of immunotherapeutics.

For more detailed information about HOOKIPA Pharma Inc (NASDAQ:HOOK) and its financial performance, please visit the company's website at or consult their filings with the Securities and Exchange Commission available at

Explore the complete 8-K earnings release (here) from HOOKIPA Pharma Inc for further details.

This article first appeared on GuruFocus.